Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ODI Pharma AB's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-0.62 Mil. ODI Pharma AB's Revenue for the
three
months ended in Mar. 2026 was kr12.71 Mil. Therefore, ODI Pharma AB's FCF Margin % for the quarter that ended in Mar. 2026 was -4.85%.
The historical rank and industry rank for ODI Pharma AB's FCF Margin % or its related term are showing as below:
XSAT:ODI'
s FCF Margin % Range Over the Past 10 Years
Min: -3671.94 Med: -1231.34 Max: 2.51
Current: 2.51
During the past 7 years, the highest FCF Margin % of ODI Pharma AB was 2.51%. The lowest was -3671.94%. And the median was -1231.34%.
XSAT:ODI's FCF Margin % is ranked worse than 50.16% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.55
vs XSAT:ODI: 2.51
ODI Pharma AB FCF Margin % Related Terms
ODI Pharma AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ODI vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ODI Pharma AB (XSAT:ODI) has a FCF Margin % of -4.85% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ODI Pharma AB and its competitors. According to the industry distribution chart, ODI Pharma AB ranks #483 out of 963 companies in the Drug Manufacturers industry, placing it in the top 50.2%.
Is ODI Pharma AB's FCF Margin % too high?
ODI Pharma AB's current FCF Margin % is -4.85%. Based on the distribution chart, ODI Pharma AB ranks #483 out of 963 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #483 out of 963 companies for FCF Margin %. This places ODI Pharma AB in the lower half of its industry. The industry median FCF Margin % is 2.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current FCF Margin % is -4.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.54 — trading 73.3% below its estimated fair value. The current FCF Margin % is -4.85%. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current FCF Margin % is -4.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.54 is trading 73.3% below its estimated GF Value™ of kr9.52.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
FCF Margin %: -4.85%
GF Value™: kr9.52 vs. price of kr2.54 (73.3% below fair value)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
